Adamas Pharmaceuticals, Inc. provided preliminary consolidated sales guidance for GOCOVRI for the fourth quarter and full year ended December 31, 2018. Based on preliminary unaudited financial information, the company expects net sales of GOCOVRI to be approximately $13.3 million for the fourth quarter ended December 31, 2018. During the fourth quarter, Adamas fulfilled approximately 5,700 paid prescriptions of GOCOVRI.

Preliminary full-year unaudited net sales of GOCOVRI are expected to be approximately $34 million, with approximately 15,500 paid prescriptions filled.

The company expects the completion of enrollment for the Phase 3 INROADS study of ADS-5102 extended release capsules for multiple sclerosis walking impairment in the first half of 2019 and release top-line data in the second half of 2019. Continue to advance ADS-4101 towards registration studies.